Literature DB >> 28096165

In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.

Patrick Grohs1, Gary Taieb1, Philippe Morand2,3, Iheb Kaibi1, Isabelle Podglajen1,3, Marie Lavollay1,3,4, Jean-Luc Mainardi1,3,4, Fabrice Compain5,3,4.   

Abstract

Ceftolozane-tazobactam was tested against 58 multidrug-resistant nonfermenting Gram-negative bacilli (35 Pseudomonas aeruginosa, 11 Achromobacter xylosoxydans, and 12 Stenotrophomonas maltophilia isolates) isolated from cystic fibrosis patients and was compared to ceftolozane alone, ceftazidime, meropenem, and piperacillin-tazobactam. Ceftolozane-tazobactam was the most active agent against P. aeruginosa but was inactive against A. xylosoxydans and S. maltophilia In time-kill experiments, ceftolozane-tazobactam had complete bactericidal activity against 2/6 clinical isolates (33%).
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Achromobacter; Pseudomonas; Stenotrophomonas; bactericidal activity; ceftolozane; cystic fibrosis

Mesh：

Substances：

Year:  2017        PMID： 28096165      PMCID： PMC5365655          DOI： 10.1128/AAC.02688-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Authors:  Yigong Ge; M J Whitehouse; Ian Friedland; George H Talbot
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.

Authors:  Frans De Baets; Petra Schelstraete; Sabine Van Daele; Filomeen Haerynck; Mario Vaneechoutte
Journal:  J Cyst Fibros       Date:  2006-06-21       Impact factor: 5.482

3.  Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Tiffany R Keepers; Marcela Gomez; Chris Celeri; Wright W Nichols; Kevin M Krause
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

4.  Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Authors:  Joseph L Kuti; Rebecca S Pettit; Natalie Neu; Jeffrey J Cies; Craig Lapin; Marianne S Muhlebach; Kimberly J Novak; Sean T Nguyen; Lisa Saiman; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2015-05-01       Impact factor: 2.803

5.  Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Authors:  Benjamin Miller; Ellie Hershberger; David Benziger; Mymy Trinh; Ian Friedland
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

6.  In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.

Authors:  Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

Authors:  David M Livermore; Shazad Mushtaq; Yigong Ge; Marina Warner
Journal:  Int J Antimicrob Agents       Date:  2009-05-09       Impact factor: 5.283

Review 8.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

9.  Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).

Authors:  Helio S Sader; David J Farrell; Mariana Castanheira; Robert K Flamm; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

Review 10.  Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Authors:  Patrick A Flume; Peter J Mogayzel; Karen A Robinson; Christopher H Goss; Randall L Rosenblatt; Robert J Kuhn; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2009-09-03       Impact factor: 21.405
View more
  5 in total

Review 1.  The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  Abdullah Tarık Aslan; Murat Akova
Journal:  Antibiotics (Basel)       Date:  2022-02-20

Review 2.  Efficacy of Combination Therapies for the Treatment of Multi-Drug Resistant Gram-Negative Bacterial Infections Based on Meta-Analyses.

Authors:  Takumi Umemura; Hideo Kato; Mao Hagihara; Jun Hirai; Yuka Yamagishi; Hiroshige Mikamo
Journal:  Antibiotics (Basel)       Date:  2022-04-14

Review 3.  Achromobacter Infections and Treatment Options.

Authors:  Burcu Isler; Timothy J Kidd; Adam G Stewart; Patrick Harris; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

4.  In Vitro Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Dale M Mazer; Carol Young; Linda M Kalikin; Theodore Spilker; John J LiPuma
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

5.  In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.

Authors:  Jeanne B Forrester; Lisa L Steed; Barbara A Santevecchi; Patrick Flume; Gloria E Palmer-Long; John A Bosso
Journal:  Open Forum Infect Dis       Date:  2018-07-02       Impact factor: 3.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.